Samarth Kulkarni sold $1.0M of CRSP
Chief Executive Officer at CRISPR Therapeutics AG. 18,568 shares at an average of $54.21, traded Feb 18, 2025, filed Feb 19, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.0M at market
- 0Share of holdings soldSold 8.9% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-023385, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 18, 2025 | MOption exercise Common Shares10b5-1 | +13,250 | - | - | 208,541 | Feb 19, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Shares10b5-1 | -11,640 | $55.05 | $641k | 196,901 | Feb 19, 2025 |
| Feb 19, 2025 | SOpen-market sale Common Shares10b5-1 | -6,928 | $52.80 | $366k | 189,973 | Feb 19, 2025 |
| Feb 18, 2025 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -13,250 | - | - | 13,250 | Feb 19, 2025 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 32Weak | CRSPsell CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $761k 13,081 shares | -6% | |
| 54Moderate | CRSPbuy CRISPR Therapeutics AG | Douglas A Treco director | $1.1M 20,000 shares | +1000% | |
| 50Moderate | CRSPbuy CRISPR Therapeutics AG | Simeon George director | $51M 989,812 shares | +1567% | |
| 21Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $141k 3,932 shares | -39% | |
| 33Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $71k 1,714 shares | -14% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $131k 3,185 shares | -4% | |
| 36Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $91k 2,197 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.